Investigational drug · Phase 2
EDP-938
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for RSV Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
13
Any phase or sponsor naming "EDP-938"
First trial start
2022
Nov 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EDP-938", any sponsor or status.
Conditions studied
As listed on its trial records.
- RSV Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "EDP-938" as an intervention, largest first.
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe DiseasePivotal-lookingRecruiting
Enanta Pharmaceuticals, IncIndustry
NCT07908381 · 860 participants (planned) · Start Oct 19, 2026 · Primary completion Jul 2029
Drug: zelicapavir; Placebo · For: RSV
Sites: Cape Coral, Florida; Miami, Florida; Bluffton, South Carolina · 4 sites in all
- A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.Pivotal-lookingCompleted
Enanta Pharmaceuticals, IncIndustry
NCT05568706 · 187 participants · Start Nov 29, 2022 · Primary completion Jun 23, 2025
Drug: EDP-938; Placebo · For: RSV Infection
Sites: Tempe, Arizona; Fresno, California; Lomita, California · 84 sites in all
- A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge ModelPivotal-lookingCompleted
Enanta Pharmaceuticals, IncIndustry
NCT03691623 · 179 participants · Start Oct 15, 2018 · Primary completion Sep 30, 2019
Drug: EDP-938 Dose 1; EDP-938 Dose 2 and 4 more · For: RSV Infection
Sites: London, United Kingdom
Enanta Pharmaceuticals, IncIndustry
NCT04816721 · 99 participants · Start Apr 26, 2022 · Primary completion Aug 19, 2024
Drug: EDP-938; Placebo · For: Respiratory Syncytial Virus (RSV)
Sites: Long Beach, California; Los Angeles, California; Sacramento, California · 78 sites in all
Enanta Pharmaceuticals, IncIndustry
NCT03384823 · 90 participants · Start Dec 7, 2017 · Primary completion Jul 3, 2018
Drug: EDP-938; Placebo · For: RSV Infection
Sites: Lenexa, Kansas
Enanta Pharmaceuticals, IncIndustry
NCT04498741 · 89 participants · Start Jul 8, 2020 · Primary completion May 27, 2021
Drug: EDP-938; EDP-938 and 6 more · For: RSV Infection
Sites: Lenexa, Kansas
Enanta Pharmaceuticals, IncIndustry
NCT04196101 · 82 participants · Start Jan 22, 2020 · Primary completion Jan 4, 2022
Drug: EDP-938; Placebo · For: Respiratory Syncytial Virus
Sites: Birmingham, Alabama; Pelham, Alabama; Anaheim, California · 29 sites in all
- A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy AdultsCompleted
Enanta Pharmaceuticals, IncIndustry
NCT06601192 · 72 participants · Start Jul 15, 2024 · Primary completion Feb 2, 2025
Drug: zelicapavir (therapeutic dose); zelicapavir (supratherapeutic dose) and 2 more · For: RSV Infection; QTc Interval
Sites: Lenexa, Kansas; San Antonio, Texas
Enanta Pharmaceuticals, IncIndustry
NCT03755778 · 72 participants · Start Nov 29, 2018 · Primary completion Jan 21, 2019
Drug: EDP-938; EDP-938 and 4 more · For: RSV Infection
Sites: Lenexa, Kansas
- Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult SubjectsCompleted
Enanta Pharmaceuticals, IncIndustry
NCT03750383 · 48 participants · Start Nov 2, 2018 · Primary completion Nov 17, 2018
Drug: EDP-938; EDP-938 and 2 more · For: RSV Infection
Sites: Lenexa, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Respiratory syncytial virus in high-risk adults: A critical appraisal of therapeutic options and unmet needs.
Mariolis I, Ranellou K, Panagiotopoulos AP, et al. · Respir Med 2026
- EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.
Levene RE, DeVincenzo J, Conery AL, et al. · J Infect Dis 2025
- Correction to: EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.
· J Infect Dis 2024
- Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development.
Sevendal ATK, Hurley S, Bartlett AW, et al. · Rev Med Virol 2024
- [EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus].
Reina J, Iglesias C · Rev Esp Quimioter 2023
- Immunity Cell Responses to RSV and the Role of Antiviral Inhibitors: A Systematic Review.
Churiso G, Husen G, Bulbula D, et al. · Infect Drug Resist 2022
Also in development for RSV Infection
- RSVpreFRESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, PF-06928316Phase 38 trials
Pfizer · Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness, Adult
- zelicapavirPhase 32 trials
Enanta Pharmaceuticals, Inc · RSV, RSV Infection, Respiratory Syncytial Virus (RSV)
- SCB-1019TPhase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- SCB-1022Phase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- SCB-1033Phase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.